With the purpose of innovatively developing new first-in-class drugs, Gtree Pharmaceuticals is currently concentrating upon development of dry eye syndrome treatment and neurotrophic keratopathy treatment that was designated as a rare disease treatment from the US FDA.
Using the success of new drug development in Korea and in the United States, Gtree Pharmaceuticals will grow as a global bio company that works across the whole world, and will continuously progress with the innovative new drug development by additionally introducing optimized global pipeline.

To achieve the vision of ‘promoting improvement in quality of life and happiness of patients,’ all employees of Gtree Pharmaceuticals are performing their missions at each respective position.
Please encourage the growth and development of Gtree Pharmaceuticals that is growing as a future sustainable company.

Company director Won S. Yang

маркетинг аудитаt1 a21l huaweib2b сайтмаркет классооо отзывы полигон